Oral therapy abrocitinib is effective in moderate-to-severe atopic dermatitis
Abrocitinib, an oral Janus kinase 1 selective inhibitor, is effective and well-tolerated in patients with moderate-to-severe atopic dermatitis, a study in JAMA Dermatology has suggested.…